| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 14/05/2024 | 14:00 | GlobeNewswire Inc. | Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET® | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 10/05/2024 | 22:00 | GlobeNewswire Inc. | Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 08/05/2024 | 22:31 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 07/05/2024 | 14:50 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 07/05/2024 | 12:00 | GlobeNewswire Inc. | Esperion Reports First Quarter 2024 Financial Results | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 29/04/2024 | 14:00 | GlobeNewswire Inc. | Esperion to Participate in Upcoming May Investor Conferences | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 23/04/2024 | 14:00 | GlobeNewswire Inc. | Esperion to Report First Quarter 2024 Financial Results on May 7 | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 07/04/2024 | 20:45 | GlobeNewswire Inc. | Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 01/04/2024 | 14:00 | GlobeNewswire Inc. | Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024 | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 26/03/2024 | 13:00 | GlobeNewswire Inc. | Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 25/03/2024 | 21:00 | GlobeNewswire Inc. | Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24 | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 22/03/2024 | 23:26 | Business Wire | U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 22/03/2024 | 20:10 | GlobeNewswire Inc. | U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 22/03/2024 | 16:04 | GlobeNewswire Inc. | CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 27/02/2024 | 15:19 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 27/02/2024 | 12:00 | GlobeNewswire Inc. | Esperion Reports Fourth Quarter and Full Year 2023 Financial Results | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 14/02/2024 | 20:14 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 13/02/2024 | 14:00 | GlobeNewswire Inc. | Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27 | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 01/02/2024 | 20:00 | GlobeNewswire Inc. | RFK, Esperion Therapeutics Announce 2024 Promotional Schedule | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 23/01/2024 | 22:00 | GlobeNewswire Inc. | Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 22/01/2024 | 12:04 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 19/01/2024 | 03:15 | GlobeNewswire Inc. | Esperion Announces Pricing of $85.1 Million Public Offering of Common Stock | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 18/01/2024 | 22:00 | GlobeNewswire Inc. | Esperion Announces Proposed Public Offering of Common Stock | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 03/01/2024 | 21:15 | Business Wire | Esperion e Daiichi Sankyo Europe annunciano un emendamento da 125 milioni di dollari alla loro collaborazione, compresa la risoluzione di una controversia in corso | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 03/01/2024 | 19:54 | Business Wire | Esperion et Daiichi Sankyo Europe annoncent une révision de leur collaboration pour un montant s’élevant à 125 millions USD, assortie de la résolution d’un litige en cours | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 03/01/2024 | 16:07 | Business Wire | Esperion und Daiichi Sankyo Europe geben Anpassung ihrer Zusammenarbeit in Höhe von 125 Millionen US-Dollar sowie die Beilegung eines anhängigen Rechtsstreits bekannt | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 03/01/2024 | 13:00 | Business Wire | Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 18/12/2023 | 14:00 | GlobeNewswire Inc. | Esperion to Participate in 42nd Annual J.P. Morgan Healthcare Conference | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 13/12/2023 | 22:46 | Dow Jones News | Esperion Therapeutics' Nexletol, Nexlizet Updates Get FDA Approval | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 13/12/2023 | 22:00 | GlobeNewswire Inc. | U.S. FDA Updates LDL-C Lowering Indication for Esperion’s NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet | NASDAQ:ESPR | Esperion Therapeutics Inc |